Clinical

Although the use of highly active antiretroviral therapy (FC) has greatly reduced the morbidity and mortality of patients infected with HIV, it is also associated with the development of adverse effects, particularly metabolic disorders like dyslipidemia.

Results of a trial presented on March 7, 2012, at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle demonstrate that hormonal contraception does not accelerate the risk for HIV progression

HIV infection cause by multiple strains of HIV at different times— called “superinfection”—can occur if a patient is repeatedly exposed to the virus, according to a study published as an abstract and presented recently at the annual Conference on Retroviruses and Opportunistic Infections.

As HIV/AIDS research continues and more drugs are developed to improve patient compliance and quality of life, it is important for specialty pharmacists to understand the drugs that will soon be making an impact on the lives of their patients.

A new injectable vaccine created to prevent HIV is set to begin its first phase of clinical trials in London.

Improvements in antiretroviral therapy have helped make significant headway in terms of the mortality and overall health of those with HIV-so why aren't more patients benefiting?